Matthew B. Stern, M.D. and Andre Ruzycky, Ph.D. Join Genome Profiling’s Scientific Advisory Board (SAB)

Matthew B. Stern, M.D. and Andre Ruzycky, Ph.D. Join Genome Profiling’s Scientific Advisory Board (SAB)

Parkinson’s Disease and Diagnostics Experts Join Genome Profiling’s SAB

(Wayne, Pennsylvania) Genome Profiling announces that two distinguished healthcare/life-science leaders have joined its Scientific Advisory Board (SAB).

Matthew B. Stern, M.D., Parker Family Professor Emeritus of Neurology and Director Emeritus of the Parkinson’s Disease and Movement Disorders Center at the University of Pennsylvania’s Perelman School of Medicine brings his world-renowned expertise in Parkinson’s and related neurologic diseases to Genome Profiling’s SAB. Dr. Stern co-founded Penn’s Parkinson’s Disease and Movement Disorders Center, which he helped build into one of the premier centers of its kind in the world. He has been principal investigator or co-principal investigator of many clinical and research studies related to Parkinson’s disease and movement disorders; and serves on numerous consulting boards. He is an inaugural member of Penn’s Academy of Master Clinicians and is a Past President of the International Parkinson and Movement Disorder Society which has awarded him its President’s Distinguished Service Award and Honorary Membership. The University of Pennsylvania recently established the Howard Hurtig-Matthew Stern Professorship in Neurology to commemorate his contributions to Penn Medicine. Dr Stern received his B.A. from Harvard University and medical degree from Duke University in Durham, North Carolina. He completed his training in neurology at the University of Pennsylvania.

Also joining Genome Profiling’s SAB is Andre Ruzycky, Ph.D. a senior corporate development executive who has served in senior innovation leadership roles for several top global medical device and diagnostics companies. He brings extensive experience in novel IVD product development and investment with a focus on cancer and infectious disease diagnostics and diagnostics platforms. Most recently Dr. Ruzycky was Vice President, Strategy and Business Development for Becton Dickinson’s Diagnostic Systems Group. Previously, he was VP Corporate Development for Hologic Inc., and Vice President, Technology Assessment at Johnson & Johnson’s Ortho Clinical Diagnostics Division. Dr. Ruzycky earned a BS Degree (biochemistry) from McMaster University, a PhD in Pharmacology from the University of Buffalo, and a MBA from the University of Pittsburgh. He began his career in medical research with Research Fellowships at Harvard Medical School and at the University of California San Francisco, followed by a faculty appointment at the University of Pittsburgh School of Medicine.

“We are very inspired by Dr. Stern and Dr. Ruzycky joining Genome Profiling’s SAB”, conveyed Jeb Connor, Genome Profiling’s Chairman, CEO and Co-Founder. “Dr Stern’s extensive clinical care and treatment knowledge in neurological diseases, particularly Parkinson’s Disease, is a valued addition to our SAB to help guide our strategy and plans in that very important disease area. Dr. Ruzycky’s extensive experience in leading the development and commercialization of world class diagnostics further strengthens Genome Profiling’s SAB and institutional expertise as our focus expands into novel immuno-diagnostics.”

According to Dr Stern, “Genome Profiling’s method for discovering novel epigenetic biomarkers, or EpiMarkers, from blood-based immune system DNA methylation profiles from patients and translating them into a simple diagnostic blood tests for diagnosis, therapeutic treatment selection, and/or disease progression monitoring for neurological diseases like Parkinson’s Disease could be game changing. Today definitive biological tests for many of these diseases do not exist.”

Dr. Ruzycky relayed, “Functional genomic profiling is likely to provide novel clinical insights for the next generation of precision diagnostic tests. Genome Profiling’s focus on characterizing the selective activation of the human immune system during the course and treatment of serious diseases such as cancer (through EpiMarkers), offers the promise of stratifying and monitoring patients who would most benefit from immuno-modulatory therapies and to identify more specific immune system therapeutic targets .”

Genome Profiling is a functional genomics company leading the decoding of the sentinel power of the immune system’s unique epigenetic responses to the stressors of disease into a new class of clinically actionable biomarkers – immune-system derived epigenetic biomarkers called EpiMarkers. Novel EpiMarkers are translated into transformational drug response prediction and diagnostic blood tests that accelerate the promise of precision health in Oncology/Immuno-Oncology and across the spectrum of non-gene-mutation-driven diseases. Genome Profiling is distinguished by its unique proprietary, cloud-based, machine-learning-enabled bioinformatics platform called the EpiMarker Platform. The platform enables the rapid profiling, discovery, and validation of each unique genome-wide immuno-epigenetic response to a disease. This information is then translated into an in silico EpiMarker that, for example, when matched with a drug can phenotypically stratify patients who will be responders vs non-responders to a using a simple blood test to improve patient selection into clinical trials and for development into a CDx for the drug. Likewise, novel EpiMarkers and their derivative tests are proving to be powerful diagnostic tools, all elucidating new clinically actionable biology beyond what current gene mutation biomarkers and techniques can achieve.

Media Contact:
Jeb Connor, Chairman, CEO and Co-Founder